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Background: The IL-32 cytokine family is associated with chronic inflammatory diseases such as Chronic
Obstructive Pulmonary Disease. However, this unique family is comprised of several alternative splicing isoforms
and their expression pattern or responses to inflammatory stimuli are unclear. We aimed to determine which IL-32
isoforms are expressed in various cell types and in chronic airway disease, as well as their response to inflammatory
stimuli.
Methods: We used several cell lines, human airway and lung primary cells from normal or chronic airway diseases
to determine the basal expression of IL-32 isoform members and their response to inflammatory cytokine
stimulations in cultured condition. We used real-time PCR to determine the gene expression of different IL-32
isoforms. We further applied hierarchical cluster analysis of the members of IL-32 based on their expression and
response to inflammatory stimuli in different cell types. Finally, we analyzed IL-32 expression from published
microarray data of different pulmonary diseases.
Results: By real-time PCR analysis, we found that IL-32B isoform expression is significantly higher in Chronic
Obstructive Pulmonary Disease, but not asthma, compared to normal lungs. Analysis of basal expression of IL-32
isoforms revealed that cell lines from various lineages including NK cells, monocytes, epithelia, and human lung tissues
have varying levels of IL-32 isoform expression. We also found that most cell types examined expressed IL-32B as the
predominant isoform while peripheral blood mononuclear cells expressed IL-32A as the major isoform. Hierarchical
clustering of IL-32 isoform based on responsiveness to inflammatory cytokines revealed that IL-32A, C, and D are
regulated similarly in most of the cell lines when stimulated by TNF-α, IL-1β, and IL-6. By contrast, IL-32B and G did not
share induction patterns with the other isoforms.
Conclusions: Our findings indicate that the specific isoform, IL-32B, but not pan-IL-32 isoforms, is elevated in Chronic
Obstructive Pulmonary Disease, and that despite low basal expression, IL-32B is highly inducible by inflammatory
cytokines in airway epithelial cells. The data also support that IL-32B is the predominant isoform and may be most
relevant to lung inflammation.
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Interleukin 32 (IL-32) is a recently described novel pro-
inflammatory cytokine that does not belong to any of
the known cytokine families [1]. It is implicated in
chronic inflammatory diseases such as rheumatoid arth-
ritis, Crohn’s disease, ulcerative colitis, psoriasis, chronic
obstructive pulmonary disease (COPD), atopic dermatitis
and tuberculosis [2–7], as well as other diseases such as
stomach cancer and in HIV replication [5, 8] (for review
see [9]). Originally reported as NK transcript 4 (NK4) in
activated T cells and IL-2 activated NK cells [10], NK4
was found to be elevated in peripheral blood mono-
nuclear cells (PBMCs) from patients receiving high dose
IL-2 therapy for metastatic melanoma [11]. Most not-
ably, NK4 was identified as an IL-18-inducible gene in
A549 lung epithelial cells transfected with the IL-18Rβ
chain, and renamed “IL-32” due to its proinflammatory
effects in vitro [1]. IL-32 is primarily expressed in im-
mune cells, including mitogen-activated T cells, activated
NK cells, and IFNγ-activated epithelial cells [12].
IL-32 is the product of a single gene, found on
chromosome 16 (16p13.3) [1]. However, six alternative
splice variants have been reported in various cell types
[4, 13–17], although much work has not been done in
this area to elucidate more definitive mechanisms of this
potential mode of regulation. Using an adenoviral over-
expression system, Henhuis et al. recently showed that
IL-32G mRNA can be spliced into IL-32B, a less potent
isoform [13]. Furthermore, IL-32D interacts with IL-32B
and inhibits its function [18, 19]. These studies suggest a
complex relationship between the IL-32 isoforms, and that
IL-32B might serve as a modulator to dampen the strong
proinflammatory effect of IL-32G. Although IL-32B is a
less potent isoform than IL-32G, it is reported to be im-
portant in enhancing vascular inflammation and develop-
ment of sepsis [20].
IL-32 sequences have not been found in the mouse
genome; however, human IL-32 acts on murine cells,
and transgenic mice carrying human IL-32 exhibit ele-
vated inflammatory cytokine expression, more infiltrated
leukocytes to tissues, and worsened sepsis, suggesting
the presence of a receptor in the mouse that can re-
spond to IL-32 [20]. However, no receptor for IL-32 has
been identified to date, although proteinase 3 (PR3) has
been identified as a soluble binding protein and while it
can activate the functional activity of IL-32, the relation-
ship and mechanism is unclear [21, 22].
As a proinflammatory cytokine, IL-32 has been re-
ported to enhance inflammation. However, paradoxical
regulatory functions have been described for IL-32.
IL-32 has been found to induce inflammatory cytokine
production in different cell types (Tumor Necrosis
Factor (TNF)-α and IL-8 in THP-1 monocytes, IL-1β and
IL-6 in PBMC, and MIP-2 in RAW macrophages [1]).Additionally, IL-32 enhances differentiation of monocytes
into macrophages in vitro [23] and induces dendritic cells
to direct Th1 and Th17 differentiation through the pro-
duction of IL-6 and IL-12 [24]. However, IL-32 can also
induce immunosuppressive cytokine IL-10 in murine
models of Dextran Sodium Sulphate (DSS)-induced col-
itis, suggesting a regulatory role during the course of DSS-
mediated inflammation [25]. Taken together, current evi-
dence suggest that IL-32 is a proinflammatory cytokine,
and effects downstream of IL-32 could be tightly regulated
during the course of inflammation. Although there have
been attempts at understanding the function of IL-32
in vivo, and the isoform expression in many cell types, it is
still unclear which isoform of IL-32 is expressed in
different diseases, and which is of higher biological
significance. Here we have analyzed the expression
patterns of IL-32 isoforms in lung disease tissues, in
various cells lines and their inducibility to inflammatory
cytokines.
Methods
Cell Culture, tissue and reagents
Wish (epithelial cell-like cell line originally derived from
amnion epithelium), A549 (alveolar basal epithelial cell
line), U937 (monocytic cell line), and primary Peripheral
Blood Mononuclear Cells (PBMC) were cultured in
10 % FBS supplemented RPMI-1640 medium, and
NK92MI (Natural Killer (NK) cell line) were cultured in
the complete NK media (Medium base: α-MEM without
ribonucleic acid, deoxyribonucleic acid, supplemented
with 2 mM L-glutamine 1.5 g/L sodium bicarbonate,
0.2 mM inositol, 0.1 mM 2-mercaptoethanol, 0.02 mM
folic acid, adjusted to 12.5 % horse serum and 12.5 %
FBS). BEAS-2B (Bronchial Epithelial cells transformed
by Ad12-SV40 virus hybrid, Bronchial epithelial cell line)
and NHBE (primary normal bronchial epithelia) cells
were cultured in LHC-9 medium (Invitrogen, Inc.) in
immersed culture conditions. The inflammatory cyto-
kines: IL-1β, IL-6, TNF-α, IFNγ, IL-17A, TGFβ, IL-13
(R&D Systems), Lipopolysaccharide (LPS), and PMA/
Ionomycin (Sigma) were used at the concentrations
(ng/ml) indicated in the figures. Differentiated primary
normal human bronchial epithelial cells (NHBE, from
three healthy donors) cultured to form a three-
dimensional model resembling the epithelial tissue of
the respiratory tract were obtained from MatTek
Corporation (Ashland, MA). Lung tissue samples from
healthy (n = 7), COPD (n = 7) and asthma (n = 4) donors
were obtained from Analytical Biological Services, Inc.
(Wilmington, DE).
RT-PCR analysis
Total RNA was harvested from A549, Wish, NK92MI,
U937, BEAS-2B, NHBE cells, and primary PBMC for
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were homogenized using a homogenizer and total RNA
extracted using RNA TRIzol reagent (Invitrogen, Inc.,
Carlsbad, CA). The expression of the five IL-32 iso-
forms in the untreated cells was determined by their
relative gene expression to Glyceraldehyde-3-Phosphate
Dehydrogenase (GAPDH) or β-actin (housekeeping
gene) in each sample. Primers were ordered from
Integrated DNA Technologies, Inc. (Coralville, IA), and













In UCSC genome database:
hIL-32G QF1 TACTTCTGCTCAGGGGTTGG
hIL-32G QR1 TGGGTGCTGCTCCTCATAATMicroarray analysis
Publicly available microarray datasets were analyzed for
the expression of IL-32 (GEO accession number
GSE13896) [26]. As described in Shaykhiev et al., micro-
array was performed on mRNA collected from Alveolar
Macrophages that were collected from bronchoalveolar
lavage (BAL), followed by an adherence step resulting in
>98 % Alveolar Macrophages [26].Analysis of data and statistics
Analyses of data were accomplished using heatmap soft-
ware in the program R (R Foundation for Statistical
Computing). The clustering of samples and probes were
performed using the hclust function. Briefly, the default
setting used for this analysis employs the Euclidian dis-
tance measures between each objects using complete
linkage method. The heat maps were drawn using the
heatmap.2 function in the gplots library. Clustering of
the IL-32 isoforms and treatments was based on log(fold
induction), and clustering of basal expression was based
on the value of (relative expression of IL-32 isoform/β-
actin). The log (treated/untreated) determines the color
of each treated sample. Red represents an increase in
gene expression, while green represents a decrease in ex-
pression in the indicated samples. Data was also analyzed
using GraphPad Prism® software (La Jolla, CA). Data are
reported as average +/− SEM, with p values (derived fromStudent’s t-test) given in the legend of the appropriate fig-
ures, and significance determined to be p < 0.05.
Results and discussion
Predominant expression of IL-32B in hematopoietic and
epithelial cells
Due to the lack of reliable and specific antibodies able to
detect individual IL-32 isoforms, we examined the ex-
pression of specific IL-32 isoforms in different human
cell types by real-time PCR. We designed primers target-
ing specific IL-32 isoforms based on the NCBI and
UCSC databases (Fig. 1). The IL32G mRNA sequence is
not found in NCBI, so we used the published IL32G se-
quence from the UCSC genome bioinformatics database
(http://genome.ucsc.edu/). The isoforms in the NCBI
database are IL-32 alpha (A), IL-32 beta (B), IL-32 epsi-
lon (C) and IL-32 delta (D), while the IL-32G sequence
is available in UCSC database and published papers.
There is a newer isoform, IL-32ζ, that has not yet been
included in the NCBI database [17]. Here, we focused
on the five major isoforms: IL-32A, B, C, D, and G, the
gene structures of which are summarized in Fig. 1.
In this study, we tested the following primary cells and
cell lines for IL-32 expression: NK92MI lymphoid cell
line, PBMC, U937 monocyte/macrophage-like cells,
Wish epithelial-like cells, A549 lung alveolar epithelial
cells, BEAS-2B airway epithelial cells, and primary
NHBE. First, we compared basal expression of the dif-
ferent IL-32 isoforms in these cell types (Fig. 2) and
found that NK92MI, U937, and Wish cells have the
highest expression of total IL-32, followed by A549. We
detected minimal expression of IL-32 isoforms in
PBMC, NHBE and BEAS-2B cells. Among the various
isoforms, IL-32B was the dominant isoform expressed
in NK92MI, U937, Wish, A549, BEAS-2B cells, and hu-
man lung tissues under basal (non-stimulated) condi-
tions. By contrast, IL-32G was the highest expressed
isoform in non-stimulated PBMCs, followed by IL-32B
and IL-32A. We also examined primary human lung
tissue and found that IL-32B was the isoform most
highly expressed and IL-32A the lowest expressed iso-
form (Fig. 2).
IL-32 family responds poorly to several proinflammatory
cytokines in NK92MI, U937, and Wish cells
We next determined the expression of IL-32 isoforms
under various inflammatory stimulation conditions.
IL-1β and TNF-α are two major cytokines that induce
IL-32 gene expression [1, 27, 28], the latter via JNK
and AKT pathways [29]. Therefore, we included these
two cytokines as well as IFNγ, IL-6, IL-17A, LPS, and
PMA/Ionomycin, to stimulate cells and analyze IL-32
isoform expression. The anti-inflammatory cytokine
TGFβ, and Th2-associated cytokine, IL-13, were
Fig. 1 Schematic of IL-32 isoforms as found in the NCBI database and primers used to analyze IL-32 isoforms A, B, C, D and G
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type tested had a different pattern of response.
As shown in Fig. 3, stimulation of PBMCs with IL-1β,
IL-6, TNF-α, LPS or PMA/Ionomycin led to increased ex-
pression of IL-32A, which becomes the dominant isoform
after cytokine stimulation. Some induction of IL-32B is
also seen by IL-1β, IL-6, and PMA/Ionomycin, but not by
TNF-α or LPS (Fig. 3a). In the NK92MI cell line, all the
isoforms are mildly induced by the proinflammatory cyto-
kines IL-1β, IL-6 and TNF-α (Fig. 3b). In U937 cells, the
IL-32B isoform is dominant and is only modestly induced
by IL-1β (10 ng/ml). Although IL-32A and IL-32C are not
the dominant isoforms, IL-32A can be induced by IL-6,
TNF-α, and LPS, while IL-32C can be induced by IL-1β,
TNF-α and LPS (Fig. 3c).
In Wish cells, IL-32B was the dominant isoform
and was only induced two fold by TNF-α, while ex-
pression of IL-32A and IL-32G were low in non-
stimulated conditions and significantly induced by
TNF-α (Fig. 3d).Fig. 2 Analysis of IL-32 isoform expression in the indicated cell lines. a Exp
expression of the housekeeping gene GAPDH. b Expression of IL-32 isoform
cell typesIL-32 family members are upregulated by several
proinflammatory cytokines in airway and lung-derived
epithelial cells: NHBE, BEAS-2B, and A549 cells
Overall IL-32 isoform expression is much lower in airway
and lung-derived epithelial cells compared to NK92MI,
U937, or Wish cell lines. However, the expression of IL-32
in these airway and lung-derived epithelial cells is highly
inducible, with IL-32B induced by more than 100-fold
upon IL-1β and TNF-α exposure in A549 cells (Fig. 3e).
In BEAS-2B epithelial cells, IL-32B, C and G are also
strongly induced by TNF-α. IL-1β and IFNγ also induced
some IL-32 isoforms, IL-32A and IL-32D, but to a lesser
extent (Fig. 3f). In NHBE cells, we also found that IL-1β,
TNF-α, and IFN-γ significantly induce IL-32 isoforms
(mainly IL-32B, C, and G). IL-6, IL-17A, and IL-13 did
not have significant effects on isoform expression. Inter-
estingly, IL-6 synergized with TGF-β to induce IL-32 iso-
form (Fig. 3g). Induction of all of the IL-32 isoforms was
statistically significant (p value ≤ 0.05 by Student’s t-test)
unless indicated.ression of IL-32 isoform in the indicated cell types as compared to the
as a proportion of total IL-32 gene expression in the indicated
Fig. 3 Analysis of IL-32 isoform induction by inflammatory cytokines in the indicated cell lines. Expression of IL-32 isoform in the indicated cell
types as compared to the expression of the housekeeping gene GAPDH following the indicated treatments. a PBMC. b NK92M1. c U937. d Wish. e A549.
f BEAS/2B. g NHBE. Induction of all the IL-32 isoforms were statistically significant (p < 0.05 by Student’s t test), unless indicated otherwise indicated
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Fig. 4 Hierarchical clustering of IL-32 isoform induction by the indicated cytokines in the indicated cell lines. Expression of the indicated IL-32 isoform in
the indicated cell types shown in Fig. 3 as analyzed by hierarchical clustering and heat map generation based on fold increase or decrease. a Clustering of
the response of each isoform in each cell type based on the relative expression of IL-32 isoform/β-actin in the untreated condition. b Clustering of the
data shown in Fig. 3 based on log10(fold induction) in response to the indicated cytokines. The log (treated/untreated) determines the color of each
treated samples
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cytokine-stimulated IL-32 isoform expression in various
cell types
By comparing the expression pattern of each IL-32 iso-
form with or without cytokine treatment, we can deter-
mine whether the induction of the different isoforms
share similar pathways in different cell types. We there-
fore analyzed the data by hierarchical clustering and
generated heat maps. Figure 4a shows the log of the
fold-induction of each IL-32 isoform in each cell type as
a heatmap and clustered based on their expression and
induction level in specific cell lines. These analyses re-
vealed that in U937, PBMC, NHBE, A549 and BEAS-2B
cells, IL32A and IL32C behave similarly, suggesting
these two isoforms may share common pathways of
regulation in these cells. By contrast, IL32A and IL32D
are more closely linked in Wish, A549 and NK92MI cell
lines; and IL-32B and IL-32G are more closely linked in
U937, PBMC, and BEAS-2B. In all cell types, IL-32B in-
duction is not closely linked to IL-32A induction, and in
most of the cells: Wish, U937, NK92MI, NHBE, A549
and BEAS-2B cells, IL-32B is not linked to IL-32D. This
analysis reveals that induction of IL-32 isoform is
uncoupled, dependent on the isoform being examined;
IL-32B and IL-32G induction behaves differently from
IL-32A, IL32C, and IL32D isoforms under TNF-α, IL-1β
and IL-6 stimulation, while IL-32A, IL-32C and IL-32D
behave more similarly in most of the cells upon stimula-
tion by these cytokines.
The ratio of the basal expression of each IL-32 isoform
to β-actin in each cell type were also plotted as heat
maps and clustered based on their expression patterns
(Fig. 4b). These analyses revealed that IL-32B is expressed
at much higher levels than the other isoforms in Wish,
NK92MI and U937 cell lines, but share comparable expres-
sion with other isoforms in BEAS-2B, A549, NHBE and
PBMC cell lines. Note that the latter cell lines express lower
levels of IL-32 in unstimulated conditions, suggesting that
increases in expression of IL-32 is largely driven by in-
creased expression of IL-32B.
Comparison of IL-32 gene expression in cells/tissues of
airway disease by microarray analyses and isoform-specific
real-time PCR
The expression of IL-32 has been implicated in a num-
ber of lung inflammatory diseases. We therefore re-
analyzed microarray data of tissues from several airwayinflammatory diseases obtained from NCBI public do-
main database. Comparing expression profiles in epithe-
lial cells and alveolar macrophages from COPD and
healthy controls, we found that IL-32 is upregulated in
COPD epithelial cells compared to healthy/non-smoker
(p = 0.0156 by Student’s t-test), but down-regulated in
COPD alveolar macrophages compared to healthy con-
trols (p = 0.0003 by Student’s t-test) (Fig. 5). By contrast,
similar analysis of microarray data from airway epithelial
cells of asthmatics, healthy controls, and smokers, re-
vealed no difference of IL-32 gene expression between
the three groups. The probes in microarray in these
studies are pan-IL-32 probes.
To determine whether lungs from patients with
chronic airway disease differentially express IL-32 iso-
forms, we examined frozen lung samples from different
airway diseases by real-time PCR (Fig. 6a). We found
that while overall IL-32 expression in COPD lungs was
similar to that seen in normal lungs, IL-32B expression
was significantly higher in lungs from COPD. However,
IL-32C expression was higher in the normal lung com-
pared to COPD lung. In contrast to COPD lungs, asth-
matic lungs expressed relatively low levels of all isoforms
of IL-32 tested compared to normal lungs. We also ex-
amined the expression of IL-1β and IL-6 in normal and
COPD lung samples by real time quantitative PCR and
found that IL-1β is significantly upregulated in COPD
lungs, with a trend towards upregulation of IL-6 which
did not reach statistical significance by Student’s t-test
(Fig. 6b,c).
IL-32 has been implicated in a number of inflamma-
tory diseases. However, there are at least five different
isoforms of this protein that can be expressed, and it is
not clear which isoform is the most important on
biological function. Previous analyses of the pattern
of expression of this cytokine has either focused on IL-
32G, or has not been clear as to which isoform was ana-
lyzed. In addition, analysis of the biological effects of IL-
32 has focused on IL-32G [8, 10, 30, 31]. In this study,
we examined the expression of the five IL-32 isoforms,
IL-32A, B, C, D and G, in several cell types as well as in
human lung tissues with airway diseases. We show that
in the absence of stimulation, the B isoform of IL-32 is
the most highly expressed in all the cell types tested in
this study, with the exception of PBMCs. In addition,
we show that the different isoforms are induced dif-
ferentially by inflammatory cytokines, which may be
Fig. 5 Microarray analysis of IL-32 expression in cells from patients with the indicated disease. a Analysis of IL-32 gene expression in Alveolar
Macrophages from healthy non-smokers (n = 24), healthy smokers (n = 34) and smokers with COPD (n = 12), non-smoker vs. COPD, p = 0.0003;
non-smoker vs. smoker, p = 0.0002; smoker vs. COPD, not significant. b Analysis of IL-32 gene expression in Airway Epithelial Cells from non-
smokers (n = 12), early COPD (n = 9), smokers (n = 12) and COPD (n = 6). non-smoker vs. COPD, p = 0.0156. Other comparisons are not statistically
significant. c Analysis of IL-32 gene expression in Airway Epithelial Cells from normal donors (n= 28), smokers (n= 16) and asthmatic at baseline (n= 42).
No significant differences observed
Fig. 6 Analysis of IL-32 isoform expression in lung tissue from patients with the indicated disease. a Expression of the indicated IL-32 isoform in
the indicated lung samples was determined by RT-PCR. Normal (n = 7), COPD (n = 7), Asthma (n = 4). b Expression of IL-1β and c) IL-6 in normal
and COPD lung samples was determined by RT-PCR. Normal (n = 4), COPD (n = 3).*p < 0.05 by Student’s t-test
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driven by increased expression of IL-32B in most cell
types and to a lesser extent, IL-32G. Finally, our data in-
dicates that while IL-32B isoform is highly expressed in
COPD lung tissues, the total IL-32 isoform gene expres-
sion in COPD lung remains the same as normal lung tis-
sues, suggesting that analysis of IL-32 isoforms may be
more informative than total IL-32 expression.
Using isoform-specific PCR primers, we have charac-
terized the response of IL-32 isoform mRNA expression
in a variety of cell types to inflammatory stimulation.
Our data indicate that depending on the origin of the
cell type, different isoforms are induced preferentially.
IL-32B is the predominant isoform in all the cell types
tested in this study, with airway and lung-derived epithe-
lial cells exhibiting the lowest basal level of IL-32 iso-
forms, but which were highly inducible. When treated
with pro-inflammatory cytokines, leukocytic cells such
as PBMC, NK92MI and U937 have predominant induc-
tion of IL-32A, while other cell types predominantly in-
duced IL-32B in response to inflammatory cytokines.
Further analysis of the behavior of these different iso-
forms under inducible conditions revealed that IL-32G
and IL-32B behave similar, but differently from the other
isoforms. Taken together with the finding that IL-32B
can be generated from IL-32G mRNA [13], this suggests
that IL-32G and B and may be linked in regulation, and
perhaps together regulate inflammation. Our data sug-
gest that IL-32 may be regulated not only at the tran-
scriptional level, but also in alternative splicing, which
seems to be cell type and stimulant specific.
Our analysis of the expression pattern of IL-32 iso-
forms indicate that while most studies have used IL-32G
to examine the biological effects of IL-32, the predomin-
ant inducible isoform in leukocytic cells is IL-32A, and
the predominant cytokine that is induced under inflam-
matory conditions in airway or lung-derived epithelial
cells is IL-32B, although this may also be related to in-
duction of IL-32G as discussed previously. More import-
antly, while the overall amount of IL-32 mRNA is the
same in COPD lung tissues compared to normal ones,
IL-32B is the predominant isoform that is significantly
up-regulated in COPD lungs. Thus IL-32B may be a
relevant biological isoform under inflammatory condi-
tions, while IL-32A may be relevant in leukocytes. To
determine whether different isoforms have different bio-
logical function, recombinant proteins from each iso-
forms, particularly IL-32B and IL32A, are needed.
Recombinant IL-32G is commercially available, and we
have attempted, with some success, to generate recom-
binant IL-32A protein. However attempts to generate re-
combinant IL-32B protein have been unsuccessful. As
mentioned earlier, Heinhuis et al. recently reported that
they were able to make IL-32B from IL-32G constructsdue to the splicing of the IL-32G mRNA when expressed
in cells. Using a mutant of the IL-32G mRNA that is un-
able to be spliced into IL-32B, they found that IL-32G
had higher activity than IL-32B [13]. Developing IL-32
isoform-specific antibodies and recombinant IL-32 iso-
form proteins will be necessary to further study the dif-
ferences in function of these spliced isoforms. With this
limited availability of IL-32 recombinant isoform pro-
teins, our preliminary data indicate that the biological
responses to IL-32A and IL-32G isoforms are also
dependent on the cell type being examined (data not
shown).
Our analysis of normal bronchial epithelial cells in tis-
sue culture conditions indicate that IL-32B is the domin-
ant isoform under both non-cytokine stimulated and
stimulated conditions. In addition, we tested IL-32 iso-
form regulation in human bronchial epithelial cells
grown under air-liquid biphasic culture. Comparison of
the two different culture conditions revealed no signifi-
cant differences in IL-32 isoform expression between air-
way bronchial cells grown under immersed and air-
liquid biphasic culture conditions. Furthermore, we
compared the expression of IL-32 isoforms between nor-
mal and COPD donors grown under air-liquid biphasic
culture and found that both normal and COPD bron-
chial cells have similar regulation of IL-32 isoforms in
response to inflammatory cytokines (unpublished data).
However, the challenges in obtaining sufficient numbers
of these air-liquid interface cultured primary bronchial
cells precluded us from making firm conclusions to de-
termine if there is a difference in response to inflamma-
tory cytokines in normal and COPD airways epithelial
cells.
Our analysis of microarray data revealed that IL-32 ex-
pression is increased in COPD patients, with increases
observed in epithelial cells, but not in lung alveolar mac-
rophages. The probes from microarray data target the
pan-IL-32 gene, therefore, information on expression of
the individual IL-32 isoforms is limited in the microarray
analysis. However, analysis of real-time PCR data of lung
tissue from such patients reveal that the predominant
isoform increased in COPD is IL-32B, while total IL-32
isoform expression in COPD lungs is similar to normal
lungs. Indeed, Rong et al. recently reported that IL-32
protein is enhanced in cigarette smoke induced pulmon-
ary inflammation [7]. By contrast, analysis of asthmatic
lung and airway epithelial cells reveals that no significant
increase in any individual IL-32 isoform. The results
from our analysis of lung samples from asthmatics was
unexpected since a recent study showed that a higher
percentage of asthmatics than normals have detectable
IL-32 in sera and sputum [32]. The discrepancy between
our IL-32 expression data in lung/airway and their
serum/sputum could be explained if there is tissue
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Indeed, such tissue specific expression of IL-32 is found
in COPD donors, as we have observed that while total
IL-32 is increased in airway epithelial cells in COPD do-
nors, it is not increased in our analysis of alveolar
macrophage or lung tissues. It is also likely that different
asthmatic populations, types of asthma and/or medica-
tion usage exhibit differential levels of IL-32 expression.
Unfortunately given that we are blinded to our donors,
we do not have this information to compare. As to the
function of IL-32 in asthma, we found that IL-13, which
can cause asthma exacerbation, does not increase any of
the IL-32 isoforms in primary NHBE cultures. Meyer
et al. found that IL-32 could inhibit angiogenesis, a
process involved in airway remodeling. Interesting, they
also observe further elevation of serum IL-32 protein
after intensive asthma therapy. The elevation of IL-32 in
allergic disease is not only observed in asthma, but also
in atopic dermatitis where IL-32 plays a role in inducing
apoptosis of keratinocytes [33]. Thus the expression of
IL-32 may be regulated differentially in different tissues
and during the pathological stages of asthma. Therefore,
future experiments to elucidate the expression and func-
tion of IL-32 in different types and stages of asthma, as
well as pre- and post-asthma therapy will be of great
interest in this field.
Conclusions
Taken together, our data suggests that IL-32B is signifi-
cantly upregulated in the inflammatory environment in
COPD lungs and airway and lung epithelial cells. This
suggests a potential role for the IL-32B isoform in
pathological conditions in chronic lung diseases that
are involved with proinflammatory cytokines, such as
TNF-α, IL-1β, and IFNγ. Our hierarchical cluster ana-
lysis shows strong correlation between IL-32B and
IL32G isoforms in terms of their responses to inflam-
matory cytokines, therefore it will be interesting to de-
termine whether like IL-32G, IL-32B can further
induce expression of inflammatory cytokines such as
IL1β or TNF-α, creating a positive feed forward loop
that contributes to the development of this disease, or
whether IL-32B is a compensatory mechanism for the
pro-inflammatory effects of IL-32G.
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